• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血清蛋白、HMMR、NXPH4、PITX1和THBS4;一组用于肝细胞癌早期诊断的生物标志物

Serum Proteins, HMMR, NXPH4, PITX1 and THBS4; A Panel of Biomarkers for Early Diagnosis of Hepatocellular Carcinoma.

作者信息

Eun Jung Woo, Jang Jeong Won, Yang Hee Doo, Kim Jooyoung, Kim Sang Yean, Na Min Jeong, Shin Eunbi, Ha Jin Woong, Jeon Soyoung, Ahn Young Min, Park Won Sang, Nam Suk Woo

机构信息

Department of Pathology, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea.

Department of Gastroenterology, Ajou University School of Medicine, Suwon 16499, Korea.

出版信息

J Clin Med. 2022 Apr 11;11(8):2128. doi: 10.3390/jcm11082128.

DOI:10.3390/jcm11082128
PMID:35456219
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9027255/
Abstract

The high morbidity rate of hepatocellular carcinoma (HCC) is mainly linked to late diagnosis. Early diagnosis of this leading cause of mortality is therefore extremely important. We designed a gene selection strategy to identify potential secretory proteins by predicting signal peptide cleavage sites in amino acid sequences derived from transcriptome data of human multistage HCC comprising chronic hepatitis, liver cirrhosis and early and overt HCCs. The gene selection process was validated by the detection of molecules in the serum of HCC patients. From the computational approaches, 10 gene elements were suggested as potent candidate secretory markers for detecting HCC patients. ELISA testing of serum showed that hyaluronan mediated motility receptor (HMMR), neurexophilin 4 (NXPH4), paired like homeodomain 1 (PITX1) and thrombospondin 4 (THBS4) are early-stage HCC diagnostic markers with superior predictive capability in a large cohort of HCC patients. In the assessment of differential diagnostic accuracy, receiver operating characteristic curve analyses showed that HMMR and THBS4 were superior to α-fetoprotein (AFP) in diagnosing HCC, as evidenced by the high area under the curve, sensitivity, specificity, accuracy and other values. In addition, comparative analysis of all four markers and AFP combinations demonstrated that HMMR-PITX1-AFP and HMMR-NXPH4-PITX1 trios were the optimal combinations for reaching 100% accuracy in HCC diagnosis. Serum proteins HMMR, NXPH4, PITX1 and THBS4 can complement measurement of AFP in diagnosing HCC and improve identification of patients with AFP-negative HCC as well as discriminate HCC from non-malignant chronic liver disease.

摘要

肝细胞癌(HCC)的高发病率主要与诊断延迟有关。因此,早期诊断这种主要死因极为重要。我们设计了一种基因筛选策略,通过预测来自人类多阶段HCC转录组数据(包括慢性肝炎、肝硬化以及早期和显性HCC)的氨基酸序列中的信号肽切割位点,来识别潜在的分泌蛋白。通过检测HCC患者血清中的分子对基因筛选过程进行了验证。从计算方法中,有10个基因元件被认为是检测HCC患者的潜在分泌标志物。血清的ELISA检测表明,透明质酸介导的运动受体(HMMR)、嗜神经素4(NXPH4)、配对样同源域1(PITX1)和血小板反应蛋白4(THBS4)是早期HCC诊断标志物,在大量HCC患者队列中具有卓越的预测能力。在鉴别诊断准确性评估中,受试者工作特征曲线分析表明,HMMR和THBS4在诊断HCC方面优于甲胎蛋白(AFP),曲线下面积、敏感性、特异性、准确性和其他值均较高。此外,对所有四种标志物与AFP组合的比较分析表明,HMMR - PITX1 - AFP和HMMR - NXPH4 - PITX1三联体是实现HCC诊断100%准确性的最佳组合。血清蛋白HMMR、NXPH4、PITX1和THBS4可在诊断HCC时补充AFP的检测,并改善对AFP阴性HCC患者的识别,以及区分HCC与非恶性慢性肝病。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e66d/9027255/30806dc1657f/jcm-11-02128-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e66d/9027255/78cb320d1078/jcm-11-02128-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e66d/9027255/e84c55c767f9/jcm-11-02128-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e66d/9027255/0804306fee9a/jcm-11-02128-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e66d/9027255/a50f0a631259/jcm-11-02128-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e66d/9027255/b37f7c89bef1/jcm-11-02128-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e66d/9027255/30806dc1657f/jcm-11-02128-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e66d/9027255/78cb320d1078/jcm-11-02128-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e66d/9027255/e84c55c767f9/jcm-11-02128-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e66d/9027255/0804306fee9a/jcm-11-02128-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e66d/9027255/a50f0a631259/jcm-11-02128-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e66d/9027255/b37f7c89bef1/jcm-11-02128-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e66d/9027255/30806dc1657f/jcm-11-02128-g006.jpg

相似文献

1
Serum Proteins, HMMR, NXPH4, PITX1 and THBS4; A Panel of Biomarkers for Early Diagnosis of Hepatocellular Carcinoma.血清蛋白、HMMR、NXPH4、PITX1和THBS4;一组用于肝细胞癌早期诊断的生物标志物
J Clin Med. 2022 Apr 11;11(8):2128. doi: 10.3390/jcm11082128.
2
Assessment of high-sensitivity C-reactive protein tests for the diagnosis of hepatocellular carcinoma in patients with hepatitis B-associated liver cirrhosis.高敏C反应蛋白检测对乙型肝炎相关性肝硬化患者肝细胞癌诊断的评估
Oncol Lett. 2017 May;13(5):3457-3464. doi: 10.3892/ol.2017.5890. Epub 2017 Mar 22.
3
Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study.血清 DKK1 作为肝细胞癌的蛋白质生物标志物:一项大规模、多中心研究。
Lancet Oncol. 2012 Aug;13(8):817-26. doi: 10.1016/S1470-2045(12)70233-4. Epub 2012 Jun 26.
4
PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma.PIVKA-II 可作为 AFP 的补充生物标志物,用于肝癌的诊断。
BMC Cancer. 2021 Apr 13;21(1):401. doi: 10.1186/s12885-021-08138-3.
5
A Large-scale, multicenter serum metabolite biomarker identification study for the early detection of hepatocellular carcinoma.一项用于肝细胞癌早期检测的大规模、多中心血清代谢物生物标志物鉴定研究。
Hepatology. 2018 Feb;67(2):662-675. doi: 10.1002/hep.29561. Epub 2018 Jan 2.
6
TEMs but not DKK1 could serve as complementary biomarkers for AFP in diagnosing AFP-negative hepatocellular carcinoma.甲胎蛋白异质体(TEMs)而非DKK1可作为甲胎蛋白(AFP)的补充生物标志物,用于诊断AFP阴性的肝细胞癌。
PLoS One. 2017 Sep 13;12(9):e0183880. doi: 10.1371/journal.pone.0183880. eCollection 2017.
7
Diagnostic value of 5 serum biomarkers for hepatocellular carcinoma with different epidemiological backgrounds: A large-scale, retrospective study.5 种血清生物标志物对不同流行病学背景肝细胞癌的诊断价值:一项大规模、回顾性研究。
Cancer Biol Med. 2021 Feb 15;18(1):256-270. doi: 10.20892/j.issn.2095-3941.2020.0207.
8
Serum epidermal growth factor-like domain 7 serves as a novel diagnostic marker for early hepatocellular carcinoma.血清表皮生长因子样结构域 7 可作为早期肝细胞癌的新型诊断标志物。
BMC Cancer. 2021 Jul 3;21(1):772. doi: 10.1186/s12885-021-08491-3.
9
Urine α-fetoprotein and orosomucoid 1 as biomarkers of hepatitis B virus-associated hepatocellular carcinoma.尿液甲胎蛋白和血清黏蛋白 1 作为乙型肝炎病毒相关性肝细胞癌的生物标志物。
Am J Physiol Gastrointest Liver Physiol. 2020 Feb 1;318(2):G305-G312. doi: 10.1152/ajpgi.00267.2019. Epub 2019 Nov 18.
10
Identification of the association between HMMR expression and progression of hepatocellular carcinoma via construction of a co-expression network.通过构建共表达网络鉴定HMMR表达与肝细胞癌进展之间的关联。
Oncol Lett. 2020 Sep;20(3):2645-2654. doi: 10.3892/ol.2020.11844. Epub 2020 Jul 9.

引用本文的文献

1
Consensus artificial intelligence-driven prognostic signature for predicting the prognosis of hepatocellular carcinoma: a multi-center and large-scale study.用于预测肝细胞癌预后的人工智能驱动的共识预后特征:一项多中心大规模研究
NPJ Precis Oncol. 2025 Jul 1;9(1):207. doi: 10.1038/s41698-025-01010-8.
2
Hepatic transcriptome profiling unveils candidate genes in cattle with liver abscesses under the influence of beef genetics in dairy cattle.肝脏转录组分析揭示了受奶牛牛肉遗传影响的患有肝脓肿的牛的候选基因。
PLoS One. 2025 Jun 9;20(6):e0324209. doi: 10.1371/journal.pone.0324209. eCollection 2025.
3
Identification and evaluation of biomarkers for diagnosis of chronic hepatitis B using RNA-seq.

本文引用的文献

1
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020:全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
2
Neurexophilin4 is a selectively expressed α-neurexin ligand that modulates specific cerebellar synapses and motor functions.神经连接蛋白 4 是一种选择性表达的 α-神经连接素配体,可调节特定的小脑突触和运动功能。
Elife. 2019 Sep 16;8:e46773. doi: 10.7554/eLife.46773.
3
A global view of hepatocellular carcinoma: trends, risk, prevention and management.
使用RNA测序技术鉴定和评估慢性乙型肝炎诊断的生物标志物。
Virus Res. 2025 Jun 4;358:199589. doi: 10.1016/j.virusres.2025.199589.
4
PITX1 as a grading, prognostic and tumor-infiltrating immune cells marker for chondrosarcoma: a public database-based immunoassay and tissue sample analysis.PITX1作为软骨肉瘤的分级、预后及肿瘤浸润免疫细胞标志物:基于公共数据库的免疫分析和组织样本分析
Front Oncol. 2025 Apr 11;15:1477649. doi: 10.3389/fonc.2025.1477649. eCollection 2025.
5
Role of Epigenetic Factors in Determining the Biological Behavior and Prognosis of Hepatocellular Carcinoma.表观遗传因素在决定肝细胞癌生物学行为和预后中的作用
Diagnostics (Basel). 2024 Aug 31;14(17):1925. doi: 10.3390/diagnostics14171925.
6
Deciphering the Molecular Complexity of Hepatocellular Carcinoma: Unveiling Novel Biomarkers and Therapeutic Targets Through Advanced Bioinformatics Analysis.解析肝细胞癌的分子复杂性:通过先进的生物信息学分析揭示新的生物标志物和治疗靶点。
Cancer Rep (Hoboken). 2024 Aug;7(8):e2152. doi: 10.1002/cnr2.2152.
7
Construction of diagnostic models for the progression of hepatocellular carcinoma using machine learning.利用机器学习构建肝细胞癌进展的诊断模型
Front Oncol. 2024 May 15;14:1401496. doi: 10.3389/fonc.2024.1401496. eCollection 2024.
8
High expression of NXPH4 correlates with poor prognosis, metabolic reprogramming, and immune infiltration in colon adenocarcinoma.NXPH4的高表达与结肠腺癌的预后不良、代谢重编程和免疫浸润相关。
J Gastrointest Oncol. 2024 Apr 30;15(2):641-667. doi: 10.21037/jgo-23-956. Epub 2024 Apr 29.
9
NXPH4 can be used as a biomarker for pan-cancer and promotes colon cancer progression.NXPH4可作为泛癌的生物标志物,并促进结肠癌进展。
Aging (Albany NY). 2024 Apr 12;16(7):5866-5886. doi: 10.18632/aging.205648.
10
PITX1 plays essential functions in cancer.PITX1在癌症中发挥着重要作用。
Front Oncol. 2023 Sep 29;13:1253238. doi: 10.3389/fonc.2023.1253238. eCollection 2023.
全球视角下的肝细胞癌:趋势、风险、预防与管理。
Nat Rev Gastroenterol Hepatol. 2019 Oct;16(10):589-604. doi: 10.1038/s41575-019-0186-y. Epub 2019 Aug 22.
4
PITX1 protein interacts with ZCCHC10 to regulate hTERT mRNA transcription.PITX1 蛋白与 ZCCHC10 相互作用,调节端粒酶逆转录酶 mRNA 的转录。
PLoS One. 2019 Aug 12;14(8):e0217605. doi: 10.1371/journal.pone.0217605. eCollection 2019.
5
The changing epidemiology of liver diseases in the Asia-Pacific region.亚太地区肝脏疾病的不断变化的流行病学。
Nat Rev Gastroenterol Hepatol. 2019 Jan;16(1):57-73. doi: 10.1038/s41575-018-0055-0.
6
Barrier to autointegration factor 1, procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3, and splicing factor 3b subunit 4 as early-stage cancer decision markers and drivers of hepatocellular carcinoma.抗自身整合因子 1、脯氨酰基赖氨酸 2-氧戊二酸 5-双加氧酶 3 和剪接因子 3b 亚基 4 作为早期癌症决策标志物和肝细胞癌的驱动因子。
Hepatology. 2018 Apr;67(4):1360-1377. doi: 10.1002/hep.29606. Epub 2018 Feb 20.
7
Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer.《1975 - 2012年美国癌症现状年度报告》,重点关注肝癌发病率上升情况
Cancer. 2016 May 1;122(9):1312-37. doi: 10.1002/cncr.29936. Epub 2016 Mar 9.
8
The Case for a Pre-Cancer Genome Atlas (PCGA).癌症前基因组图谱(PCGA)的理由。
Cancer Prev Res (Phila). 2016 Feb;9(2):119-24. doi: 10.1158/1940-6207.CAPR-16-0024. Epub 2016 Feb 1.
9
Biomarkers for the early diagnosis of hepatocellular carcinoma.肝细胞癌早期诊断的生物标志物。
World J Gastroenterol. 2015 Oct 7;21(37):10573-83. doi: 10.3748/wjg.v21.i37.10573.
10
Elevated alpha-fetoprotein: differential diagnosis - hepatocellular carcinoma and other disorders.甲胎蛋白升高:鉴别诊断——肝细胞癌和其他疾病。
Clin Liver Dis. 2015 May;19(2):309-23. doi: 10.1016/j.cld.2015.01.005. Epub 2015 Feb 27.